[144] Maze Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Maze Therapeutics insider plans a new stock sale. A Form 144 notice shows that Catherine Sohn intends to sell up to 26,920 shares of Maze Therapeutics common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,052,784.67. The shares are listed as being sold on NASDAQ, with an approximate sale date of January 7, 2026, and 48,119,444 common shares outstanding.

The filing states that the 26,920 shares were acquired on January 7, 2026 via a stock option exercise from the issuer, paid in cash. It also discloses that during the past three months, Catherine Sohn sold 2,493 Maze Therapeutics common shares on January 6, 2026 for gross proceeds of $96,269.69. By signing, the seller represents they are not aware of undisclosed material adverse information about the company.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	26920	1052784.67	48119444	01/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/07/2026	Stock Option Exercise	Issuer			26920	01/07/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CATHERINE SOHN 171 Oyster Point Blvd Suite 300 South San Francisco CA 94080	Common	01/06/2026	2493	96269.69

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider transaction is disclosed for MAZE in this Form 144?

The notice states that Catherine Sohn plans to sell up to 26,920 shares of Maze Therapeutics common stock, with an aggregate market value of $1,052,784.67.

How were the 26,920 Maze Therapeutics (MAZE) shares acquired?

The filing reports that the 26,920 common shares were acquired on January 7, 2026 via a stock option exercise from the issuer, paid in cash.

When and where are the MAZE shares expected to be sold?

The Form 144 lists an approximate sale date of January 7, 2026 for the 26,920 common shares, to be sold on the NASDAQ market.

Which broker is handling the Maze Therapeutics Form 144 sale?

The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

How many Maze Therapeutics shares are outstanding in this notice?

The Form 144 lists 48,119,444 Maze Therapeutics common shares outstanding in connection with the planned sale.

What prior Maze Therapeutics share sales by this insider are disclosed?

Over the past three months, Catherine Sohn is reported to have sold 2,493 Maze Therapeutics common shares on January 6, 2026 for gross proceeds of $96,269.69.

What representation does the insider make in the Maze Therapeutics Form 144?

By signing, the person for whose account the securities are to be sold represents that they do not know any material adverse information about Maze Therapeutics’ current or prospective operations that has not been publicly disclosed.